Endometrial Cancer

Disease State Hub

FDA Alerts

FDA ALERT

FDA Approves Pembrolizumab With Chemotherapy to Treat Primary Advance or Recurrent Endometrial Carcinoma in Patients

09/13/2024

Jessica Ganga

In June, following a placebo-controlled trial, the FDA approved pembrolizumab with chemotherapy to treat patients with primary advanced or recurrent endometrial carcinoma.

09/13/2024

menopause

FDA Approves Menopausal Status Test

10/26/2018

The FDA has approved a test to help determine a patient’s menopau

10/26/2018

Expert Q&A

Expert Q&A

The Fate of Gynecological Oncology

06/04/2024

Stephanie Blank, MD, answers questions about the session she hosted at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer titled “The Future is Now: Determining the Fate of...

06/04/2024

conference coverage

Novel Agents in the Treatment of Patients With HER2-Positive Endometrial Cancer

03/31/2024

Kari E. Hacker, MD, PhD

  In this video, Kari E. Hacker, MD, PhD, discusses the results of her team's study examining the rate of HER2-expression among patients with endometrial cancer, as well as the eligibility of these...

03/31/2024

conference coverage

Outcomes of Minimally Invasive Surgery vs Laparotomy for Stage II Endometrial Cancer

10/21/2024

Christian Dagher, MD

  In this video, Christian Dagher, MD, discusses the results of his team's study comparing the oncologic outcomes associated with treatment of stage II endometrial cancer with minimally invasive...

10/21/2024